Indicated for: thrombocytopenia
Route of administration: injectable
Substance: romiplostim (fusion protein)
ATC: B02BX04 (Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics)
Romiplostim is a thrombopoietin receptor agonist used in the treatment of primary immune thrombocytopenia (ITP) in patients who do not respond to other therapies such as corticosteroids or immunoglobulins. It stimulates platelet production by activating thrombopoietin receptors on megakaryocyte progenitor cells in the bone marrow.
Romiplostim is administered as a subcutaneous injection, usually once weekly, with the dose adjusted based on the patient's platelet levels. It is used to reduce the risk of bleeding and improve the quality of life for patients with chronic ITP.
Common side effects include headache, fatigue, nausea, and muscle pain. In rare cases, severe adverse reactions such as thrombosis or bone marrow fibrosis may occur. Regular monitoring of blood counts and overall health is essential during treatment.
Romiplostim is an effective therapeutic option for patients with ITP, helping to increase platelet counts and reduce the risk of bleeding complications.